^
    Back
    Association details:
    Biomarker:PIK3CA E545K
    Cancer:Breast Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Res
    Title:

    PI3K Hyperactivation Results in Lapatinib Resistance that is Reversed by the mTOR/PI3K Inhibitor NVP-BEZ235

    Excerpt:
    ...we have identified that the two most prevalent breast cancer mutations in PIK3CA (E545K and H1047R) also confer resistance to lapatinib.
    DOI:
    10.1158/0008-5472.CAN-08-1740